WDL
ALXN

Well Done LLC’s Alexion Pharmaceuticals ALXN Stock Holding History

Well Done LLC’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-221
Closed -$22K – 708
2018
Q4 		$22K Buy
+221
New +$26.1K 0.01% 344
2018
Q2 		– Sell
-266
Closed -$30K – 560
2018
Q1 		$30K Buy
+266
New +$31.8K 0.01% 281

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Well Done LLC's ALXN Position: Q1 2019 in Review

Well Done LLC sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 221 shares — an estimated $22K sold.

Well Done LLC first reported a position in ALXN in Q1 2018 and held it in 2 quarters. The position peaked at $30K in Q1 2018. 611 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

  • Well Done LLC reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Well Done LLC sold 221 Alexion Pharmaceuticals shares in Q1 2019, an estimated $22K.
  • Well Done LLC first reported a position in Alexion Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Well Done LLC's Alexion Pharmaceuticals position peaked at $30K in Q1 2018.
  • 611 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Well Done LLC's 13F filing for Q1 2019, filed 9 May 2019.